Introducing Arthrosamid®

Redefining treatment for knee OA, without surgery

Arthrosamid® is a non-biodegradable 2.5 iPAAG injectable implant that delivers long-lasting pain relief — improving the quality of life for patients with knee OA.

OSP ARTHROSAMID 0472 copy
Arthosamid box orange

What is Arthrosamid®?

Arthrosamid® is a single, minimally invasive, long-lasting knee OA treatment — a non-biodegradable injectable polyacrylamide hydrogel (2.5 iPAAG) for intra-articular use.

Relieve pain and improve the function of the knee affected by knee OA, with a simple, one-step outpatient procedure.

Long lasting icon

Pioneering

Arthrosamid® is a first-in-class synovial scaffolddelivered as a single, minimally invasive out-patient procedure performed under local anaesthesia, with ultrasound guidance.

Without surgery icon

Proven

Arthrosamid® is safe for intended use and has undergone more than 20 years of research and development.

Proven icon

Pain Relief Treatment

A single, minimally invasive, long-lasting knee OA treatment, Arthrosamid® has demonstrated an improvement in quality of life with patients in clinical trials reporting a reduction in pain by Week 4 — and lasting over 3 years.

What is 2.5 iPAAG?

Intra-articular injectable polyacrylamide hydrogel (2.5 iPAAG) in Arthrosamid® is made up of 2.5% cross-linked polyacrylamide and 97.5% water.

 

  • Biocompatible: permeable to salts and organic molecules the hydrogel is able to integrate with soft tissue
  • Viscoelastic: cross-linked chains of polymer allow flexible shea
  • Non-degradable: structural stability of hydrogel provides longevity of action

     

iPAAG: injectable polyacrylamide hydrogel

Undergone

over 20 years

of research and development

Around

1,200,000 syringes of 2.5 iPAAG

have been made for human use.

Arthrosamid® remains

safe and effective

for its intended use 3 years after treatment.

Biocompatible

permeable to salts and organic molecules the hydrogel is able to integrate with soft tissue

Viscoelastic

cross-linked chains of polymer allow flexible shear

Non-degradable

structural stability of hydrogel provides longevity of action

Arthrosamid® is the first and only approved 2.5 iPAAG treatment that permanently integrates into the synovial membrane — decreasing joint stiffness, diminishing pain, and improving the function of the knee.

Acting as a synovial scaffold , Arthrosamid® distributes within the synovial fluid to fully integrate into the synovial membrane , thickening it and providing a physical barrier that breaks the inflammatory cycle to relieve pain.

Mode of Action — let’s take a closer look

Untreated OA knee: the synovial fluid loses its viscoelastic properties. The synovial membrane contains an accumulation of inflammatory cells that are a precursor to pain and swelling.

Arthrosamid is injected into the joint cavity, distributes within the joint fluid, and begins to adhere to the synovial lining.

Macrophage-like synoviocytes (MLS) enter the hydrogel but are unable to phagocytise it.

The MLS cells differentiate into fibroblast-like synoviocytes (FLS) which start integrating through the hydrogel, creating a thin vessel-bearing fibrous network.

A new layer of intima forms on the top of the integrated iPAAG synovial membrane. This new layer consists of scattered non-inflammatory type cells, with the iPAAG acting as a scaffold within the sub-intima layer. This process takes 1 month.

The thickening of the synovial sub-intima layer causes distancing of the inflammatory cells and breaks the inflammatory cycle.

Untreated OA knee: the synovial fluid loses its viscoelastic properties. The synovial membrane contains an accumulation of inflammatory cells that are a precursor to pain and swelling.

MOA Step 1 01

How to inject Arthrosamid®

Procedure 01

Click or scroll to continue

Oral antibiotics must be taken 1-2 hours before injection to reduce risk of infection. If available, use Ultrasound to ensure correct placement of needle into knee joint space.

-2:00

Procedure 02

2. Conduct the procedure using aseptic conditions and a no-touch technique. Swab at least 5cm around the injection site and use a local anaesthetic to numb the skin around it. Prepare 6 x 1ml Arthrosamid® syringes by removing from blister packs and laying on table for easy access.

0:00

Procedure 03

Swab knee again, 5cm around injection site. Ideally, use a 21G sterile needle with Luer Lock fitting in lateral, proximal recess of knee joint. The same needle must stay within knee for the whole procedure. Remove joint effusion, if present, before injecting Arthrosamid®.

0:05

Procedure 04

Remove the syringe if used for effusion, but keep the needle in place. Remove the protective Tip Cap from Arthrosamid® syringe using forceps.

0:07

Procedure 05

Turn the syringe tight on the Luer Lock to ensure the needle is firmly in the socket and mounted correctly. Press firmly on the syringe and inject 1ml of Arthrosamid® into the synovial cavity. Repeat until the recommended dosage of 6ml of Arthrosamid® is delivered into the synovial cavity.

0:08

Procedure 06

Using forceps, remove the needle from the knee. Swab the knee for a third time over the injection site and cover it with a plaster. Discard the syringe, needle and any unused material after treatment.

0:10

Ready to take the next step?

Pioneering, proven pain treatment for knee OA. Contact us to use Arthrosamid® iPAAG in your knee osteoarthritis patients today.